In particular, an Icelandic case-control study suggests that RA and PS patients taking TNF-α inhibitors have an increased risk of developing in situ squamous cell carcinoma but not invasive squamous cell carcinoma or basal cell carcinoma [109]. The gene discussed is TNF; the disease is rheumatoid arthritis.